Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
Article excerpt
Highlighted: the sentence this signal was extracted from
SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN ) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results "Illumina delivered strong results during the second quarter. Momentum continued to build through the first half of 2026, as our technology is enabling clinical customers to expand sequencing-intensive applications. Based on this performance, we are increasing our revenue and earnings guidance for the year," said Jacob Thaysen, Chief Executive Officer of Illumina. "Demand for NovaSeq X remains high as we expand our workflow and multiomics capabilities, broadening the value of Illumina's ecosystem." Fiscal year 2026 guidance For fiscal year 2026, we now expect: Second quarter results GAAP Non-GAAP (a) Dollars in millions, except per share amounts Q2 2026 Q2 2025 Q2 2026 Q2 2025 Revenue $ 1,159 $ 1,059 $ 1,159 $ 1,059 Gross margin 66.4 % 65.6 % 68.2 % 69.4 % Operating profit $ 245 $ 214 $ 260 $ 252 Operating margin 21.1 % 20.2 % 22.5 % 23.8 % Diluted EPS $ 1.35 $ 1.49 $ 1.31 $ 1.19 (a) See tables in "Results of Operations - Non-GAAP" section below for GAAP and non-GAAP reconciliations. Capital expenditures for free cash flow purposes were $39 million for Q2 2026. Cash flow provided by operations was $201 million, compared to $234 million in the prior year period. Free...
Keep reading with a free account
The rest of this article, and every signal for Illumina, is in your free account.
